Patients diagnosed with prostate cancer initially respond to androgen ablation therapy with tumor cells undergoing apoptosis, but then the patients relapse in time and develop metastatic, androgen independent prostate cancer. Docetaxel has been widely used for treatment of patients with advanced metastatic prostate cancer. The sphingolipid, ceramide, is a lipid second messenger that mediates a lot of functions as regulation of cell growth, proliferation, differentiation, senescence and apoptotic responses in various cancer cells. The enzyme, glucosylceramide synthase (GCS) is responsible for bioactivation of the proapoptotic mediator ceramide to antiapoptotic glucosylceramide. Likewise, sphingosine kinase-1 (SK-1) transforms apoptotic ceramide to antiapoptotic sphingosine 1-phosphate. Emerging results indicate that GCS and SK-1 are overexpressed in resistant cancer cell lines and cancerous tissue samples of patients. Moreover apoptosis and inhibition of cell proliferation and survival are induced by intracellular ceramide levels including enhancement in de novo ceramide production, exogenous delivery of cell permeable ceramide and inhibition of ceramide metabolism by affecting GCS and SK-1. In this study, we applied exogenous ceramide and inhibitors of GCS and SK-1 in combination with docetaxel for sensitizing androgen independent prostate cancer cells to chemotherapy and provide their effectively utilization with minimizing side effects of the drugs. The de novo generation of ceramide is regulated by the genes (LASS1-6) in mammalian cells. Therefore in this study, we examined the possible roles of the ceramide/S1P and ceramide/GS by examining expression levels of GCS, SK-1 and LASS1,2,4,5,6 which can play important roles to overcome androgen independent.